Welcome!

News Feed Item

JSS Medical Research Inc. and Integrated Research Inc. in Montréal, Québec, Canada completes the strategic merger of the two companies to become the largest Canadian owned CRO

MONTREAL, Jan. 7, 2014 /PRNewswire/ - JSS Medical Research Inc. (JSS), a full-service international Contract Research Organization (CRO), announced today that it has completed the acquisition of Integrated Research Inc. (IRI), a Canadian CRO located in Dollard-des-Ormeaux, Quebec. The transaction results in the strategic merger of the two companies with IRI continuing to operate as a fully-owned subsidiary of JSS.

IRI was founded over two decades ago by Joanne E. Watson M.Sc. and it provides clinical research support to pharmaceutical, device, and biotechnology companies. The company's core service offering includes study start-up, project management, site management, data management, and monitoring covering a wide range of therapeutic areas. With clinical operations as its foundation, and owing to its in-depth knowledge and understanding of regulatory matters, and extensive network of experienced clinical researchers, IRI has become a leading Canadian CRO with an impeccable reputation for providing the highest quality of comprehensive and flexible study management.

JSS Medical Research was also founded approximately twenty years ago by Dr. John S. Sampalis a Clinical Epidemiologist from McGill University. Clinical Research, Medical Science, Epidemiology and Biostatistics were the cornerstones of the foundation of JSS. Clinical Operations were incorporated on the scientific foundation and hence the company evolved as a fully integrated CRO offering services that include strategic consulting, study conceptualization, study design, protocol development, execution, project management, site management, monitoring, data management, biostatistical consulting and analysis, and medical writing. The company has earned an international reputation as one of the leading scientific CROs with significant expertise in pre- and post-approval epidemiological studies.

"This is an important milestone for JSS and IRI as well as for the Canadian Industry. The merger of JSS and IRI creates a robust and stable Canadian based and owned CRO that has the critical mass, expertise and most importantly, experienced senior management that will offer highest quality services covering all of the scientific and operational aspects of clinical research. Now a local CRO will be able to provide the same services as the large multinationals, while maintaining the intimate client relationships that have contributed to our longevity and client loyalty over the last twenty years" stated Dr. John S. Sampalis, CEO and President of JSS Medical Research.

"For our international and global clients, the merger with IRI, in combination with the recent acquisition of Latam Clinical Trials, provides significant advantages. We now have augmented our operational and regulatory expertise across several jurisdictions and expanded the clinical research team to allow us to easily manage our local and international studies. In addition, our clients will benefit from our Quality Assurance Program which has been audited and tested by several of our global clients" said Ms. Stella Boukas, V.P. Clinical Operations of JSS.

"From a financial perspective, the synergies of JSS and IRI will provide our clients with a stronger CRO that can address all of their service needs with conservative costs. In the current CRO market where costs are an important second consideration for the selection of service providers, JSS-IRI will offer competitive pricing at uncompromised quality. At the same time the merger of the two companies will reduce overhead and other costs and will contribute to our continued financial stability and growth" stated Dr. Toni Rinow, CFO of JSS.

"Widespread adoption of outsourcing has changed the clinical services landscape over the past five years with strategic relationships with the 10 large CROs dominating the market. Smaller CROs have to adapt their business strategies to meet the changing needs of sponsors. JSS Medical Research has pursued its journey in becoming a niche provider in late phase studies by excelling in scientific methods for conducting research. We have gained strategic advantage as market leader in Post Marketing Observational Studies, Health Economic Outcome Research and a proven track record in medical writing, publications and presentations at scientific conferences. The merger with IRI will strengthen our position in Canada and provide the foundation for our continued expansion while at the same time enabling us to continue to deliver high quality research to our Canadian and international clients" said Dr. Sanjay Machado, Executive Director Global Business Operations of JSS.

"In an industry that is both dynamic and volatile, our growth strategy is driven by the demands and the needs of our clients. More specifically, our expansion in Latin America, which began with the acquisition of Latam and will continue with others in Chile, Argentina and Brazil, has resulted from the increasing requirements for epidemiological and post marketing studies by regional health authorities and payers in these regions. The merger with IRI has also been driven by the need for a Canadian CRO that can provide comprehensive high quality turnkey services to the Canadian Affiliates of International Pharmaceuticals and Canadian biotech companies. Integrated Research's philosophy with emphasis on high quality clinical operations governed by integrity and responsiveness to their clients was entirely compatible with the JSS Medical Research's vision" concluded Dr. Sampalis.

"The pace of growth at JSS Medical Research sees us joining a company at a very exciting time and being part of this group will enable us to better leverage our expertise, offering our local and international clients access to additional complementary services provided by senior personnel with the highest possible level of scientific expertise and knowledge in clinical trial operations," said Joanne Watson, founder and CEO of Integrated Research. "Both companies' business ethic is focused on a commitment to excellence and quality and this philosophy is only further reinforced by the combination of the two organizations."

About JSS Medical Research

JSS Medical Research is a full-service CRO with its corporate office in Montreal, Canada and a regional office in Colombia. The company offers clinical trial management services in Phase I-IV trials in a broad range of therapeutic areas and is a leader in Post-Approval Clinical Epidemiology Studies (PACES) including Post-Marketing Observational Studies, Health Outcomes Research and Health Economics. Personalized services with one-on-one client attention from experienced senior scientific and clinical teams have established JSS Medical Research as a unique niche CRO worldwide. Currently JSS Medical Research is conducting research studies in over 20 countries around the world for its clients which include the top 20 global pharmaceutical companies.

www.jssresearch.com.

About Integrated Research Inc.

Integrated Research Inc. is a Canadian contract research organization providing clinical research management services and expert assistance to pharmaceutical and biotechnology firms worldwide in the development of their therapeutic agents.  Headquartered in Montreal, its highly skilled team offers a complete range of services and guidance in Phase II, III, and IV studies, post-marketing surveillance programs, and Investigator-driven research initiatives. For over 21 years, IRI has prided itself on meeting the challenges of research by providing innovative solutions along with the flexibility and professionalism you expect when outsourcing your clinical research needs.

SOURCE JSS Medical Research Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...